In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a new risk of non-melanoma skin cancer (NMSC) (basal cell carcinoma, squamous cell carcinoma) in patients treated with hydrochlorothiazide....
In agreement with the South African Health Products Regulatory Authority (SAHPRA), Aurobindo Pharma (Pty) Ltd would like to inform you of the following important information regarding the risk of Hemophagocytic Lymphohistiocytosis (HLH) associated with the use of lamotrigine containing medicines....
lngelheim Pharmaceuticals (Pty) Ltd and Sanofi-Aventis South Africa (Pty) Ltd in collaboration with SAHPRA wish to inform you of the following safety information update regarding the use of hyoscine butylbromide injection as contained in BUSCOPAN 20 mg/1 ml ampoules and BUSCOPAN COMPOSITUM 20 mg/2,5 g...
In collaboration with the South African Health Products Regulatory Authority (SAHPRA) Bristol-Myers Squibb and Key Oncologies (Ply) Ltd would like to draw your attention to the risk of errors in prescribing, dispensing, preparing and administering different parenteral formulations of amphotericin B. ...
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), JANSSEN PHARMACEUTICA (PTY) LTD, would like to inform you of the risk of severe cutaneous adverse reactions in patients treated with Eprex®. ...
The following pharmaceutical companies: AXIM Pharmaceuticals (Pty) Ltd, Guerbet South Africa (Pty) Ltd and GE Healthcare SA in collaboration with South African Health Products Regulatory Authority (SAHPRA) would like to inform you of the safety information regarding the risk of gadolinium brain deposition following the...
ViiV Healthcare would like to inform you of a potential safety issue which has been brought to our attention by the Principal Investigator of the above study conducted in Botswana. The potential safety issue is related to Neural Tube Defect (NTD) cases in infants born...
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACE inhibitors / Angiotensin Receptor Blockers (ARBs) and fluoroquinolones....
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACEIs / Angiotensin Receptor blockers (ARBs) and fluoroquinolones....
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with Angiotensin Converting Enzyme Inhibitors (ACEIs) Angiotensin receptor blockers (ARBs) and fluoroquinolones....